ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2025

Erratum: Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.